Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

Name: A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy — clinical trial record (NCT06612775)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Trial Details

NCT Number	NCT06612775
Lead Sponsor	Shanghai Zhimeng Biopharma, Inc.
Conditions	Focal Epilepsy
Enrollment	180 participants
Start Date	2024-09
Primary Completion	2026-08 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2024-09-25